CXCR4 Expression as a Prognostic Biomarker in Soft Tissue Sarcomas

Poor long-term survival in localized high-risk soft tissue sarcomas (STSs) of the extremities and trunk highlights the need to identify new prognostic factors. CXCR4 is a chemokine receptor involved in tumor progression, angiogenesis, and metastasis. The aim of this study was to evaluate the associa...

Descripción completa

Detalles Bibliográficos
Autores: Virgili Manrique, Anna Cristina|||0000-0001-9733-6034, Salazar, Juliana|||0000-0002-3581-4499, Gallardo, Alberto|||0000-0002-2514-2027, López Pousa, Antonio, Terés Lleida, Raúl|||0009-0006-2831-1136, Bagué Rosell, Sílvia|||0000-0001-9980-7231, Orellana Fernández, Ruth|||0000-0003-1260-7064, Fumagalli, Caterina|||0000-0002-8614-7622, Mangues, Ramon|||0000-0003-2661-9525, Alba Castellón, Lorena, Unzueta Elorza, Ugutz|||0000-0001-5119-2266, Casanova Rigat, Isolda|||0000-0002-1196-4724, Sebio, Ana|||0000-0003-3333-2370
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:294261
Acceso en línea:https://ddd.uab.cat/record/294261
https://dx.doi.org/urn:doi:10.3390/diagnostics14111195
Access Level:acceso abierto
Palabra clave:CXCR4
Prognostic factor
Soft tissue sarcomas
Synovial sarcomas
Undifferentiated pleomorphic sarcomas
Descripción
Sumario:Poor long-term survival in localized high-risk soft tissue sarcomas (STSs) of the extremities and trunk highlights the need to identify new prognostic factors. CXCR4 is a chemokine receptor involved in tumor progression, angiogenesis, and metastasis. The aim of this study was to evaluate the association between CXCR4 expression in tumor tissue and survival in STSs patients treated with neoadjuvant therapy. CXCR4 expression was retrospectively determined by immunohistochemical analysis in serial specimens including initial biopsies, tumors post-neoadjuvant treatment, and tumors after relapse. We found that a positive cytoplasmatic expression of CXCR4 in tumors after neoadjuvant treatment was a predictor of poor recurrence-free survival (RFS) (p = 0.003) and overall survival (p = 0.019) in synovial sarcomas. We also found that positive nuclear CXCR4 expression in the initial biopsies was associated with poor RFS (p = 0.022) in undifferentiated pleomorphic sarcomas. In conclusion, our study adds to the evidence that CXCR4 expression in tumor tissue is a promising prognostic factor for STSs.

Similares en LA Referencia